All In Biotech

Drug Trial Radar · NCT06963502

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

A Phase Ib Study Evaluating the Safety, Tolerability , Pharmacokinetics,Activity and Immunogenicity of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

762

Planned (sponsor's estimate)

Start

May 30, 2025

Primary completion

Dec 31, 2028

Study completion Apr 30, 2030

Sponsor

Sponsor type
Industry
First posted
May 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in and Colorectal cancer(CRC) and non-Small cell lung cancer (NSCLC).

Conditions

  • Advanced Solid Tumors
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer

Interventions

  • HS-10370Drug

    Participants will receive HS-10370 dose 1 administered orally

  • HS-20117Drug

    Participants will receive HS-20117 given as dose 3 intravenous infusion(IV) once every 14-day cycle.

  • AdebrelimabDrug

    Participants will receive Adebrelimab intravenous infusion(IV) once every 21-day cycle

  • CapecitabineDrug

    Participants will receive Capecitabine administered orally

  • OxaliplatinDrug

    Participants will receive Oxaliplatin intravenous infusion(IV) once every 21-day cycle.

  • Folinic Acid, Fluorouracil and Oxaliplatin/IrinotecanDrug

    Participants will receive Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan intravenous infusion(IV) once every 14-day cycle.

  • HS-20093Drug

    Participants will receive HS-20093 intravenous infusion(IV) once every 21-day cycle

  • platinum (cisplatin or carboplatin)Drug

    Participants will receive platinum (cisplatin or carboplatin) administered IV in 21-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Event(s) (AEs)Time frame: From Cycle 1 Day 1 (C1D1) to disease progression or death, up to 2 years (each cycle is 14 days).

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • Sun Yat-sen University Cancer Center

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.